GlassScriptPhysician profile
Tej Bhavsar
NPI 1689725301
$18,383.88
in general payments reported to CMS, 2019-2025
33 companies · $4,866 in 2025
The $4,866 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,649 · 2020: $1,008 · 2021: $345 · 2022: $1,545 · 2023: $3,302 · 2024: $3,668 · 2025: $4,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $608 · Education: $278 · Travel and Lodging: $39.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,912.02 |
| Consulting Fee | $607.50 |
| Education | $277.92 |
| Travel and Lodging | $39.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,738.94 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $2,504.38 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,410.36 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $1,732.40 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,221.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,074.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,060.69 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $773.14 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $771.48 | 2022-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $624.67 | 2023-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $495.43 | 2019-2025 | |
| Lilly USA, LLC | $471.83 | 2019-2024 | Taltz, Olumiant |
| Genentech USA, INC. | $291.60 | 2019 | |
| Sobi, INC | $266.93 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $247.98 | 2021-2025 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $240.65 | 2019-2025 | Orencia |
| Invivyd INC | $193.21 | 2025 | Pemgarda |
| Organon LLC | $157.95 | 2023-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $146.30 | 2023-2025 | Idacio |
| Alexion Pharmaceuticals, INC. | $142.61 | 2024 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $136.97 | 2023-2025 | Uptravi, Opsumit |
| Radius Health, INC. | $129.56 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.70 | 2019-2023 | Ofev |
| Horizon Therapeutics Plc | $82.89 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.85 | 2019 | |
| Sandoz INC. | $71.87 | 2024-2025 | Hyrimoz |
| Hikma Pharmaceuticals USA | $47.20 | 2019-2020 | |
| Antares Pharma, INC. | $45.36 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.46 | 2025 | Truxima |
| Octapharma USA, INC. | $24.40 | 2025 | Octagam Immune Globulin (Human) |
| Pacira Pharmaceuticals Incorporated | $20.74 | 2024 | Zilretta |
| Tonix Medicines, INC. | $17.47 | 2025 | Tonmya |
| Fidia Pharma USA INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tej Bhavsar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.